Evaluating the Impact of EnteraGam In People With COVID-19

Covid19 Clinical Trial

— PICNIC  

Official title:

Randomized Open-Label Clinical Study Evaluating the Impact of EnteraGam, a Nutritional Intervention Containing Bovine Plasma-Derived Immunoglobulin CoNcentrate, on Clinical Outcomes In People With COVID-19

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04682041
• Other study ID #: PICNIC Study
• Status: Completed
• Phase: N/A
• Start date: December 22, 2020
• Est. completion date: February 21, 2022

Study information

• Verified date: April 2023
• Source: Entera Health, Inc
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Background:

Coronavirus Disease 2019 (COVID-19), caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), emerged as a potentially life-threatening disease in Wuhan, China, at the end of 2019. Since then, it has spread to almost 200 countries and infection rates are rapidly accelerating.

Overactivation of T cells resulting in immune dysfunction, dysfunction of the renin angiotensin system, and antibody-dependent enhancement are thought to contribute to the cytokine storm that results in acute respiratory distress syndrome (ARDS), culminating in death. In addition to causing respiratory symptoms, SARS-CoV-2 can cause diarrhea and has been isolated from the stool. SARS-CoV-2 binds to Angiotensin-converting enzyme 2 (ACE2) on lung alveolar type 2 cells, but ACE2 is also expressed in the absorptive enterocytes from the ileum and colon. The diarrhea may be caused by increased intestinal permeability due to binding of these receptors by the SARS-CoV-2.

Thus, an intervention to attenuate this cytokine storm may improve clinical outcomes in people with COVID-19. One such intervention is oral administration of serum bovine immunoglobulins, which decreases interleukin-6 (IL-6) levels safely with minimal side effects. Animal and human clinical studies have shown dietary supplementation with oral immunoglobulins improves mucosal immunity, specifically respiratory/pulmonary and GI mucosa, and decreases systemic inflammation, reducing the symptoms and severity of pulmonary inflammation and viral infections.

Hypothesis:

Dietary supplementation with EnteraGam® will decrease IL-6 levels and prevent disease progression in SARS-CoV-2 infected individuals.

Objectives:

To evaluate the effectiveness of the oral nutritional therapy EnteraGam® (serum-derived bovine immunoglobulin/protein isolate) to prevent disease progression of COVID-19 and to decrease IL-6 levels as compared to standard of care in subjects with COVID-19.

Methods:

Randomized open-label clinical study evaluating the effectiveness of EnteraGam® 10.0 g BID (every 12 hours) added to standard of care, as compared to standard of care alone, in subjects with COVID-19.

Description:

Subject population:

Outpatient and inpatient male and non-pregnant females ≥18 years old, diagnosed with COVID-19 in the emergency department or admitted to the hospital but not requiring invasive mechanical ventilation or in the ICU.

Approximately 420 subjects will be randomized (2:1 ratio), 280 in the EnteraGam® arm and 140 in the control (standard of care) arm.

Nutritional intervention:

ImmunoLin is the active ingredient in EnteraGam®, a medical food developed and marketed by Entera Health in the US since 2013. ImmunoLin is an edible bovine plasma-derived immunoglobulin concentrate developed in 2001 as an immunoglobulin enriched plasma preparation for the human dietary supplement market. ImmunoLin is Generally Regarded as Safe (GRAS) following a letter of no objection from the US FDA in 2008. Physicians have prescribed EnteraGam® for patients with a variety of GI-related conditions.

Statistical methodology:

Efficacy: Based on per protocol analysis. Subjects lacking an assessment at Week 2 will be included in the analysis using the last available post-baseline data. Three pre-specified secondary analyses will be performed: 1) restricted to subjects with a comorbidity considered a major risk factor for hospitalization and disease severity (diabetes, cardiovascular disease, chronic lung disease, chronic renal disease, immunocompromised state); 2) restricted to age ≥ 50 years; 3) by inpatient only and outpatient only subgroups.

Additional analysis of covariance models with adjustment for Baseline characteristics and interactions may be examined in supportive or exploratory analyses.

Safety: All safety analyses will be based on all subjects who are randomized to EnteraGam and subsequently receive at least 1 packet of investigational product. Safety assessments will be analyzed by frequency of events/abnormalities for categorical values or summarized using descriptive statistics (mean, standard deviation, median, range, and number of observations).

Recruitment information / eligibility

• Status: Completed
• Enrollment: 200
• Est. completion date: February 21, 2022
• Est. primary completion date: December 20, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Subject is =18 years of age.

2. Male or female. Females of childbearing (reproductive) potential must have a negative urine pregnancy test at screening.

3. Subject with diagnosis of COVID-19 based on + RNA or immunoglobulin M (IgM) test or compatible clinical presentation* who:

1. is being discharged from the emergency department without hospitalization, or

2. is admitted to the hospital or was previously hospitalized and still in the hospital, does not require invasive mechanical ventilation and does not require management in the intensive care unit. Inpatients can be enrolled in the study at any time of their hospitalization, if they comply with the inclusion criteria.

(*)Compatible clinical presentation will consider compatible symptoms (cough, fever, myalgia, dyspnea, ageusia / anosmia) and examination of general condition, heart rate and respiratory rate, oxygen saturation, cardiopulmonary auscultation, compatible radiology.

4. Ability to consume EnteraGam.

5. Subject or surrogate decision maker is capable of understanding the requirements of the study, understands the language of the informed consent form, and is capable and willing to sign the informed consent form.

Exclusion Criteria:

1. Female subjects who are pregnant or breast-feeding.

2. Subject is enrolled in another randomized clinical trial.

3. Subject is taking anti-IL-6 treatment (e.g. tocilizumab), anti-IL-1 treatment (e.g. canakinumab, anakinra), or other biologic immunomodulators or immunosuppressant drugs. Note: Topical/inhaled immunomodulators and corticosteroids are not restricted.

4. Subject has immediate need for GI surgery or intervention for active GI bleeding, pancreatitis, peritonitis, intestinal obstruction, or intra-abdominal abscess.

5. Subject has active inflammatory bowel disease (e.g., ulcerative colitis, Crohn's disease, or celiac disease), GI malignancy, GI obstruction, pancreatitis, gastroparesis, carcinoid syndrome, amyloidosis, ileus, or cholelithiasis.

6. Subject has active gastric ulcer, duodenal ulcer, diverticulitis, colitis, enteritis, infectious gastroenteritis, or GI neoplasm, other than benign polyps.

7. Subject has a history of allergy or intolerance to beef or to any ingredient in the product.

8. Subject has active drug or alcohol abuse that in the opinion of the investigator may interfere with the subject's ability to comply with this protocol.

9. History of uncontrolled psychiatric disorders (includes significant depression or suicidal ideation), that in the opinion of the investigator may interfere with the subject's ability to comply with this protocol.

10. In the opinion of the investigator, progression to death is imminent and highly likely within the next 24 hours.

Related Conditions & MeSH terms

• COVID-19
• Covid19

Intervention

Dietary Supplement:
• Bovine Plasma-Derived Immunoglobulin Concentrate
EnteraGam® 10.0 g, containing 5.0 g of serum-derived bovine immunoglobulin/protein isolate (SBI) BID (every 12 hours) for 2 weeks.

Other:
• Standard of care
Standard of care PSMAR protocol for COVID-19 patients.

Locations

Country	Name	City	State
Spain	Hospital del Mar	Barcelona

Sponsors (3)

Lead Sponsor	Collaborator
Entera Health, Inc	Clinical Research Unit, IMIM (Hospital del Mar Medical Research Institute), Lemus Buhils, SL

Country where clinical trial is conducted

Spain, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Incidence of Adverse Events	Incidence of serious and non-serious adverse events.	From baseline to Week 2
Primary	Change in plasma IL-6 levels	Variation of IL-6 levels measured in plasma	From baseline to Week 2
Primary	COVID-19 disease progression by Week 2	Percentage of patients with COVID-19 who have disease progression by Week 2, defined as: For outpatients, return to emergency department for COVID-19 related manifestations or worsening of =1 level on the World Health Organization (WHO) 9-point ordinal scale.; For inpatients, worsening of =1 level on the WHO 9-point ordinal scale.	From baseline to Week 2
Secondary	Change in dyspnea	Variation of dyspnea presentation at Week 2 compared to baseline, assessed by daily symptoms questionnaire	At Week 2
Secondary	Change in diarrhea	Variation of diarrhea presentation at Week 2 compared to baseline, assessed by daily symptoms questionnaire	At Week 2
Secondary	Change in fever	Variation of fever presentation at Week 2 compared to baseline	At Week 2
Secondary	Change in neutrophil count	Variation of neutrophil count at Week 2 compared to baseline	At Week 2
Secondary	Change in lymphocyte count	Variation of lymphocyte count at Week 2 compared to baseline	At Week 2
Secondary	Change in neutrophil/lymphocyte ratio	Variation of neutrophil/lymphocyte ratio at Week 2 compared to baseline	At Week 2
Secondary	Change in platelet count	Variation of platelet count at Week 2 compared to baseline	At Week 2
Secondary	Change in C-reactive protein	Variation of C-reactive protein levels at Week 2 compared to baseline	At Week 2
Secondary	Change in ferritin	Variation of ferritin levels at Week 2 compared to baseline	At Week 2
Secondary	Change in D-dimer	Variation of D-dimer levels at Week 2 compared to baseline	At Week 2
Secondary	Change in AST	Variation of Aspartate Transaminase (AST/GOT) levels at Week 2 compared to baseline	At Week 2
Secondary	Change in ALT	Variation of Alanine Transaminase (ALT/GPT) levels at Week 2 compared to baseline	At Week 2
Secondary	Time to worsening clinical status	Time elapsed between baseline and disease progression, defined as: For outpatients, return to emergency department for COVID-19 related manifestations or worsening of =1 level on the WHO 9-point ordinal scale.; For inpatients, worsening of =1 level on the WHO 9-point ordinal scale.	From baseline to Week 2